{"id":"inhaled-fluticasone-propionate","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Oropharyngeal candidiasis"},{"rate":"5-10","effect":"Dysphonia/hoarseness"},{"rate":"1-5","effect":"Tremor"},{"rate":"5-15","effect":"Headache"},{"rate":"1-5","effect":"Nervousness/anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"When inhaled, fluticasone propionate acts locally in the lungs to inhibit the release of inflammatory mediators from immune cells, reduce mucus production, and decrease airway edema. This anti-inflammatory action reduces airway hyperresponsiveness and improves airflow in obstructive airway diseases. The inhaled route delivers the drug directly to the site of inflammation while minimizing systemic exposure.","oneSentence":"Fluticasone propionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:47.973Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06052267","phase":"PHASE3","title":"A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-08-30","conditions":"Asthma","enrollment":2700},{"nctId":"NCT06372496","phase":"PHASE4","title":"Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-04-16","conditions":"Asthma","enrollment":1366},{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT06664619","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-12-12","conditions":"Asthma","enrollment":724},{"nctId":"NCT02476825","phase":"PHASE4","title":"A Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids on Adult Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospitals, Leicester","startDate":"2016-01-20","conditions":"Healthy","enrollment":30},{"nctId":"NCT07282886","phase":"PHASE2","title":"VENTURI (VENTilation Using Respiratory Imaging)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-15","conditions":"Asthma","enrollment":20},{"nctId":"NCT05922761","phase":"PHASE2","title":"BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-05-31","conditions":"Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases","enrollment":45},{"nctId":"NCT07396987","phase":"NA","title":"Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Juan Carlos Cardet","startDate":"2026-02","conditions":"Asthma Attack, Asthma Control, Asthma Exacerbations","enrollment":40},{"nctId":"NCT07223294","phase":"PHASE3","title":"Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma","status":"NOT_YET_RECRUITING","sponsor":"Sandoz","startDate":"2026-04","conditions":"Respiratory","enrollment":1430},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT06905483","phase":"PHASE4","title":"Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2025-04-01","conditions":"COPD, Chronic Obstructive Pulmonary Disease (COPD), Small Airway Disease","enrollment":22},{"nctId":"NCT07329946","phase":"NA","title":"Immuno-inflammatory Response of Erdosteine in COPD","status":"NOT_YET_RECRUITING","sponsor":"Pierachille Santus, MD, PhD","startDate":"2026-02-28","conditions":"COPD","enrollment":30},{"nctId":"NCT07324707","phase":"PHASE2","title":"Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma","status":"RECRUITING","sponsor":"Anhui Palo Alto Pharmaceuticals, Inc.","startDate":"2025-10-15","conditions":"Bronchial Asthma","enrollment":30},{"nctId":"NCT07318350","phase":"PHASE3","title":"Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-10","conditions":"Moderate Asthma","enrollment":174},{"nctId":"NCT07315555","phase":"NA","title":"Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-01-01","conditions":"Community Acquired Pneumonia","enrollment":90},{"nctId":"NCT05735431","phase":"PHASE3","title":"Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-06","conditions":"Moderate Asthma","enrollment":""},{"nctId":"NCT05535972","phase":"PHASE4","title":"To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":463},{"nctId":"NCT05292053","phase":"PHASE4","title":"Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2022-07-01","conditions":"Copd","enrollment":80},{"nctId":"NCT04885530","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":10956},{"nctId":"NCT07052942","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care (Full Study)","status":"RECRUITING","sponsor":"DARTNet Institute","startDate":"2025-08-01","conditions":"Asthma, Asthma Attack, Asthma Exacerbations","enrollment":3200},{"nctId":"NCT07192016","phase":"PHASE4","title":"129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":60},{"nctId":"NCT06040268","phase":"PHASE1, PHASE2","title":"Advair HFA in Healthy and HAPE Predisposed Subjects","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-12-12","conditions":"Altitude Edema","enrollment":60},{"nctId":"NCT04655508","phase":"PHASE3","title":"Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-21","conditions":"Stem Cell Transplant Complications, Respiratory Disease, Bronchiolitis Obliterans","enrollment":35},{"nctId":"NCT06858137","phase":"NA","title":"Thread Embedding Acupuncture For Rhinitis Allergy","status":"COMPLETED","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2024-12-15","conditions":"Rhinitis Allergic","enrollment":64},{"nctId":"NCT06290102","phase":"PHASE1","title":"Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-05-16","conditions":"Asthma","enrollment":30},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT03248128","phase":"PHASE3","title":"Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-20","conditions":"Asthma","enrollment":906},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":"Asthma, Bronchial Diseases, Respiratory Tract Infections","enrollment":103},{"nctId":"NCT06077019","phase":"NA","title":"Role of Lung Function for Exercise Capacity in Well-trained Individuals","status":"RECRUITING","sponsor":"Morten Hostrup, PhD","startDate":"2023-10-03","conditions":"Exercise Performance","enrollment":60},{"nctId":"NCT01202097","phase":"PHASE3","title":"A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-08","conditions":"Asthma","enrollment":334},{"nctId":"NCT06552364","phase":"PHASE4","title":"Air Pollution and Inhaled Corticosteroids in COPD","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-04-01","conditions":"COPD","enrollment":48},{"nctId":"NCT03141424","phase":"PHASE4","title":"Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2022-06-01","conditions":"Asthma","enrollment":20},{"nctId":"NCT02989935","phase":"PHASE4","title":"RELVAR Effects on Parasternal Muscle Activity, Diaphragm, and Ventilation in Severe COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Calgary","startDate":"2016-04","conditions":"Copd","enrollment":30},{"nctId":"NCT06234345","phase":"PHASE3","title":"Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1252},{"nctId":"NCT01396278","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":9},{"nctId":"NCT03040596","phase":"PHASE1","title":"The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children","status":"TERMINATED","sponsor":"Joseph Dohar, MD","startDate":"2017-03-01","conditions":"Vocal Fold Nodules","enrollment":2},{"nctId":"NCT03072849","phase":"","title":"Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2015-04","conditions":"Bronchiolitis Obliterans Syndrome","enrollment":23},{"nctId":"NCT06650917","phase":"PHASE1","title":"Acupoint Massage Combined With Ear Point Pressing Beans","status":"COMPLETED","sponsor":"Hai'an Hospital of TCM001","startDate":"2016-01-01","conditions":"Asthma","enrollment":120},{"nctId":"NCT05192499","phase":"NA","title":"Respiratory Dysbiosis in Preschool Children with Asthma: Predictive of a Severe Form","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2022-02-04","conditions":"Asthma in Children, Dysbiosis","enrollment":30},{"nctId":"NCT03199976","phase":"PHASE4","title":"Efficacy of Intermittent Tiotropium in Early Childhood Wheezing","status":"TERMINATED","sponsor":"Helsinki University Central Hospital","startDate":"2016-04-20","conditions":"Wheezy Bronchitis, Asthmatic Bronchitis, Wheezing","enrollment":80},{"nctId":"NCT00545324","phase":"PHASE4","title":"First Step With Singulair® Therapy (0476-323)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09","conditions":"Asthma","enrollment":399},{"nctId":"NCT00489346","phase":"PHASE3","title":"A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-10","conditions":"Asthma, Bronchial","enrollment":994},{"nctId":"NCT04527016","phase":"PHASE4","title":"Airway Microbiota Based Treatment of Asthma in Preschool Children","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2021-10-18","conditions":"Asthma in Children","enrollment":120},{"nctId":"NCT00424008","phase":"PHASE3","title":"Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":"Asthma","enrollment":722},{"nctId":"NCT00379288","phase":"PHASE3","title":"Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06","conditions":"Asthma","enrollment":404},{"nctId":"NCT00127166","phase":"PHASE3","title":"Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Exercise Induced Asthma","enrollment":154},{"nctId":"NCT02889809","phase":"PHASE4","title":"Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-07-10","conditions":"Asthma","enrollment":477},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT06025214","phase":"PHASE1","title":"Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-08-22","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT05982990","phase":"PHASE1","title":"Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-08-01","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT05736874","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-08-06","conditions":"Covid19","enrollment":1407},{"nctId":"NCT00995475","phase":"PHASE4","title":"A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-10","conditions":"COPD","enrollment":18},{"nctId":"NCT04072887","phase":"PHASE2","title":"Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-09-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":974},{"nctId":"NCT04503460","phase":"PHASE4","title":"Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2021-07-23","conditions":"Asthma","enrollment":24},{"nctId":"NCT00521222","phase":"NA","title":"Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2007-06","conditions":"Asthma","enrollment":90},{"nctId":"NCT04665895","phase":"PHASE3","title":"A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-12-09","conditions":"Asthma","enrollment":451},{"nctId":"NCT04265105","phase":"PHASE2, PHASE3","title":"Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2021-12-22","conditions":"Asthma","enrollment":18},{"nctId":"NCT04677959","phase":"PHASE4","title":"A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2021-02-16","conditions":"Asthma","enrollment":427},{"nctId":"NCT05697003","phase":"PHASE1","title":"Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-02-17","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT05748977","phase":"EARLY_PHASE1","title":"Short Acting Agents Vs Long Acting in Frequent Excerbator COPD Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-02-20","conditions":"Copd","enrollment":80},{"nctId":"NCT05664061","phase":"PHASE3","title":"Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-01-30","conditions":"Asthma","enrollment":451},{"nctId":"NCT02593123","phase":"PHASE2","title":"Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2015-11-04","conditions":"Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma","enrollment":31},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT02440009","phase":"PHASE2, PHASE3","title":"A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2014-05","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":191},{"nctId":"NCT01397162","phase":"PHASE2","title":"Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-21","conditions":"Asthma","enrollment":29},{"nctId":"NCT01397201","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":30},{"nctId":"NCT03387852","phase":"PHASE2","title":"Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-12","conditions":"Asthma","enrollment":296},{"nctId":"NCT01092143","phase":"PHASE2","title":"BI 671800 ED in Steroid-naive Asthmatic Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-03-18","conditions":"Asthma","enrollment":389},{"nctId":"NCT01103349","phase":"PHASE2","title":"BI 671800 in Asthmatic Patients on Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-04-20","conditions":"Asthma","enrollment":243},{"nctId":"NCT05397834","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2022-05-11","conditions":"Asthma, Bioequivalence","enrollment":36},{"nctId":"NCT05363202","phase":"PHASE3","title":"To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma","status":"UNKNOWN","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2022-04-15","conditions":"Bronchial Asthma","enrollment":790},{"nctId":"NCT03363503","phase":"PHASE4","title":"Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD","status":"TERMINATED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2018-04-13","conditions":"COPD","enrollment":64},{"nctId":"NCT01090024","phase":"PHASE2","title":"Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-03-01","conditions":"Asthma","enrollment":108},{"nctId":"NCT05342558","phase":"PHASE4","title":"Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.","status":"COMPLETED","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2017-09-19","conditions":"COPD","enrollment":133},{"nctId":"NCT04946630","phase":"NA","title":"Explorative Clinical Investigation to Investigate the Ability of PreciseInhale to Direct Regional Lung Targeting and Reduce the Degree of Throat Deposition and Subsequent Gastrointestinal Absorption in Healthy Volunteers After Inhalation of Test Drug Substances Via the PreciseInhale System","status":"COMPLETED","sponsor":"Inhalation Sciences Sweden AB","startDate":"2021-06-07","conditions":"Nebulizers and Vaporizers","enrollment":12},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT02215122","phase":"PHASE1","title":"Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2013-10","conditions":"Asthma, COPD","enrollment":40},{"nctId":"NCT02474017","phase":"PHASE1","title":"An Open Study to Assess the Robustness of the CRC749 Inhaler","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2015-05","conditions":"Asthma, COPD","enrollment":111},{"nctId":"NCT02245672","phase":"PHASE3","title":"MGR001 / Advair Diskus Local Equivalence Study in Asthma","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2014-10","conditions":"Asthma","enrollment":1128},{"nctId":"NCT00540839","phase":"PHASE3","title":"A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2007-11","conditions":"Asthma, Bronchial","enrollment":""},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02437604","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-05","conditions":"Asthma","enrollment":43},{"nctId":"NCT02980133","phase":"PHASE3","title":"Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-12-28","conditions":"Asthma","enrollment":841},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT02680561","phase":"PHASE1","title":"A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-04","conditions":"Asthma","enrollment":20},{"nctId":"NCT01738087","phase":"PHASE2","title":"Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-11","conditions":"Asthmatic","enrollment":30},{"nctId":"NCT05085587","phase":"PHASE1","title":"Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2021-10-01","conditions":"Bioequivalence, Asthma","enrollment":18},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT03756883","phase":"PHASE3","title":"Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2018-12-03","conditions":"Asthma","enrollment":999},{"nctId":"NCT05054322","phase":"PHASE2, PHASE3","title":"FLuticasone in cOvid Treatment (FLOT)","status":"UNKNOWN","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2021-09-22","conditions":"Covid19","enrollment":500},{"nctId":"NCT05021887","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2021-08-13","conditions":"Asthma, Bioequivalence","enrollment":50},{"nctId":"NCT03219255","phase":"","title":"RELVAR® 100 ELLIPTA® Special Drug Use Investigation (COPD, Long-term)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-08-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1047},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT04953741","phase":"PHASE4","title":"A Comparative Study on the Efficacy of Different Stepping-down Therapy for Childhood Asthma","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2021-08-01","conditions":"Asthma in Children","enrollment":90},{"nctId":"NCT04746040","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2021-01-18","conditions":"Bioequivalence, Asthma","enrollment":50},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":311,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Inhaled Fluticasone Propionate","genericName":"Inhaled Fluticasone Propionate","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone propionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory cytokine production. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}